Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 18, Issue 12, Pages 1029-1040Publisher
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2018.1544494
Keywords
Extracellular vesicles; tumor-derived exosomes; cancer; non-invasive biomarkers
Categories
Funding
- NIH [RO-1 CA168628, R-21 CA205644]
- NATIONAL CANCER INSTITUTE [R01CA168628, R21CA205644] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Introduction: Liquid biopsy platforms are being actively developed in the biomarker field. Extracellular vesicles (EVs), especially the tumor-derived exosome (TEX) subsets of EVs, represent a platform that allows for molecular and genetic profiling of parent tumor cells. TEX are ubiquitous in body fluids of cancer patients and are promising clinically relevant surrogates of cancer cells. Areas covered: Isolation from body fluids of cancer patients and subsetting of exosomes based on immunoaffinity capture offers a means of evaluating proteins, lipids, nucleic acids and other molecular contents that are a characteristic of TEX and exosomes produced by reprogrammed normal cells. The same liquid biopsy can inform about the status of a tumor and simultaneously evaluate the competency of immune cells to mediate anti-tumor activities. Expert commentary: TEX and reprogrammed non-TEX isolated from plasma of cancer patients have the potential to become non-invasive biomarkers of cancer diagnosis, prognosis and response to therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available